Reuters: Regulatory News: FDA approves Bayer drug for rare gastrointestinal tract cancer

Reuters: Regulatory News Reuters.com is your source for breaking news, business, financial and investing news, including personal finance and stocks. Reuters is the leading global provider of news, financial information and technology solutions to the world's media, financial institutions, businesses and individuals. // via fulltextrssfeed.com

FDA approves Bayer drug for rare gastrointestinal tract cancer Feb 25th 2013, 19:06 WASHINGTON | Mon Feb 25, 2013 2:06pm EST WASHINGTON Feb 25 (Reuters) - The U.S. Food and Drug Administration said on Monday it has approved Bayer AG's drug Stivarga for the treatment of a rare type of gastrointestinal tract cancer. Stivarga is already approved to treat colon cancer that has progressed after prior treatment or that has spread to other parts of the body. Bayer will now also be able to market the drug as a treatment for gastrointestinal stromal tumors (GIST). Stivarga, known chemically as regorafenib, was tested in 199 patients with GIST that could not be surgically removed and had progressed after treatment with other therapies. Patients taking Stivarga had a delay in tumor growth progression that was on average 3.9 months later than patients given a placebo.

You are receiving this email because you subscribed to this feed at blogtrottr.com. If you no longer wish to receive these emails, you can unsubscribe from this feed, or manage all your subscriptions